- Shuffle
Toggle OnToggle Off
- Alphabetize
Toggle OnToggle Off
- Front First
Toggle OnToggle Off
- Both Sides
Toggle OnToggle Off
Front
How to study your flashcards.
Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key
Up/Down arrow keys: Flip the card between the front and back.down keyup key
H key: Show hint (3rd side).h key
![]()
PLAY BUTTON
![]()
PLAY BUTTON
![]()
83 Cards in this Set
- Front
- Back
|
What is the formula for blood pressure?
|
BP = CO x TPR
|
|
Explain the "vicious cycle of heart failure"
|
Poor ventricular performance --> poor perfusion --> body increases vasoconstriction, increases Na retention --> increases ventricular dilation...
This is a "non-correcting cycle" |
|
According to the Starling Curve, ______ _______ increases with LVFP.
|
According to the Starling Curve, CARDIAC OUTPUT increases with LVFP.
|
|
Name four important inotropes
|
1. Digoxin
2. Dobutamine 3. Dopamine 4. Inamrinone |
|
Digoxin: M of A
|
Na/K ATPase
|
|
Dobutamine: what does it do?
|
beta-1 agonist
|
|
Dopamine: what does it do?
|
beta-agonist, NE release
|
|
Digoxin: M of A
|
Inhibit Na/K ATPase --> intracellular Na up --> Na/Ca exchanger can't function, so intracellular Ca rises --> contractility up
|
|
Digoxin: derived from what?
|
Foxglove
|
|
Digoxin: pharmacology
|
Long half-life (1.5 -2 days, thus hard to get rid of if things go wrong)
Typically given as a loading dose followed by maintenance. |
|
Digoxin: Major clinical impact
|
Reduction in the number of hospitalizations due to CHF
|
|
Digoxin: What does it do?
|
Improves contractility
Inhibits AV node conduction |
|
Digoxin: elimination
|
Renal - may require dose adjustment
|
|
Digoxin: alternate names?
|
Digitalis, Foxglove
|
|
Digoxin: AE
|
- Increased automaticity
- Heart block - Hyperkalemia ("You can't have Dig tox without hyperK) - "Van Gogh" like visual changes - GI effects |
|
Digoxin: drug interactions
|
Interacts with many other CV agents (amiodarone)
|
|
Digoxin: antidote
|
Binding antibody
|
|
"You can't have digoxin toxicity without ____________."
|
"You can't have digoxin toxicity without HYPERKALEMIA."
|
|
Dobutamine: route
|
IV
|
|
Dobutamine: what is it?
|
Potent beta-1 agonist with peripheral alpha-1 activity (keeps BP steady)
Good because doesn't stimulate beta-2 receptors in the skeletal muscules, causing hypotension. |
|
Dobutamine: what does it do?
|
- Increases CO
- Reduces heart filling pressures - Lowers TPR (i.e. the increased tone seen with hypoperfusion goes away) |
|
Dobutamine: major problems associated with what?
|
With increased HR and myocardial oxygen demand
|
|
"Dobutamine Holiday": what is it?
|
When a patient is admitted and put on IV dobutamine to transiently improve myocardial performance.
|
|
Dobutamine: does it improve mortality?
|
No.
|
|
Dopamine: route
|
IV
|
|
Dopamine: what does it do?
|
Beta-1 agonist, releases NE
Raises BP, improves contractility. |
|
Dopamine: used most often to do what?
|
To raise BP
|
|
Dopamine: AE
|
Tachycardia, increased myocardial oxygen demand, can lower the threshold for arrhythmias.
Dopamine is essentially "flogging the system" Can make those with coronary artery stenosis very ischemic |
|
Dopamine: effects at low dose, effects at high dose
|
At low dose: can cause some vasoconstriction
At high dose: beta-1 activity and NE release. NE release is not so good, so is only used in the short term |
|
Dopamine: used mainly for what?
|
BP control
|
|
Inamrinone: what is it?
|
A phosphodiesterase inhibitor used to treat CHF
An agent of last resort, after dobutamine |
|
Inamrinone: route
|
IV
Oral forms not available due to toxicity and increased mortality (milrinone) |
|
Inamrinone: AE
|
Cardiac arrhythmias, hypotension
|
|
Inamrinone: M of A?
|
Inhibits phosphodiesterase (which degrades cAMP) --> increased intracellular cAMP.
Targets both the vasculature and the heart. cAMP up in the heart = revs up cAMP in periphery = vasodilation |
|
Levosimendan: availability
|
Only available outside the US
|
|
Levosimendan: what does it do?
|
Sensitizes myocytes to ambient Ca levels --> works to provide more inotropy from endogenous levels of catecholamines.
|
|
Levosimendan: M of A
|
Binds to cardiac troponin C in a calcium-dependant manner
Also produces vasodilation by activating ATP-sensitive K channels in smooth muscle cells |
|
Levosimendan: used for whom?
|
Very decompensated CHF patients (Class IV).
|
|
Levosimendan: AE
|
Hypotension
Arrhythmias Hypokalemia (b/c of effects on K channels) |
|
Excess preload reduction comes at the expense of what?
|
Cardiac output.
|
|
Thiazides: AE
|
Hypokalemia
|
|
c/c potency of loop diuretics and thiazides.
|
Loop diuretics are much more potent
|
|
c/c the hypokalemia associated with loop diuretic use vs. thiazide use
|
Hypokalemia due to loop diuretic use is more severe.
|
|
Nitroprusside: route
|
IV only
|
|
Nitroprusside: dilates which vessels?
|
Both arterial and venous
|
|
Nitroprusside: AE
|
Liberation of cyanide from the thiocyanide complex with NO leads to toxicity.
|
|
Nitroprusside: what does it do?
|
Drops blood pressure and filling pressures.
|
|
What the general philosophy about how to lower preload?
|
By increasing venous pooling (nitroglycerine/nitroprusside) or by reducing intravascular volume (diuretics)
|
|
Aldosterone antagonists: mortality and morbidity with CHF
|
Both reduced!
|
|
Spironolactone: what is it?
|
A K-sparing aldosterone antagonist. A synthetic steriod.
|
|
Spironolactone: AE
|
Can cause hyperkalemia and gynecomastia
|
|
Eplerenone: what is it?
|
A non-steroidal aldosterone receptor antagonist.
|
|
Eplerenone: pharmacology
|
- Longer half-life (4-6 hrs) than Spironolactone
- Metabolized by CYP3A4 |
|
Eplerenone: AE
|
Hyperkalemia
|
|
Eplerenone: drug interactions
|
Metabolized by CYP3A4, so can interfere with other CYP-metabolized drugs like cyclosporine, simvastatin
|
|
ACEi: primarily reduce _______.
|
ACEi: primarily reduce AFTERLOAD.
|
|
ACEi: benefits
|
- Prevents pathologic remodeling of the heart (interrupt neurohumoral stimulation)
- Improves outcomes in patients with low ejection fraction. |
|
Both aldosterone antagonists and ACEi have what affect on potassium?
|
Increase
|
|
ACEi: have to keep an eye on what?
|
Creatinine
|
|
ACEi: AE
|
Cough and renal toxicity (ACEi --> GFR down --> creatinine up)
|
|
ARBs: name two
|
Losartan, valsartan
|
|
ARBs: predominantly reduce what?
|
Afterload.
|
|
ARBs: benefits
|
- Prevent pathologic remodeling of heart
- Improve outcomes in patients with a low ejection fraction |
|
ARBs: AE
|
Renal toxicity (but no cough)
|
|
ARBs: what are they?
|
Antagonists to the AII type 1 receptor.
|
|
Every CHF that can tolerate them should be on what?
|
Beta-blockers
|
|
c/c magnitude of benefit of ACEi vs. beta-blockers
|
Beta-blockers have a greater magnitude of benefit.
|
|
What is a good way to think about ANP and BNP?
|
As the "damage signals" of the myocytes
|
|
Beta-blockers: used for what class of HF?
|
Class II and Class III
|
|
Nesiritide: what is it?
|
Recombinant B-type (brain) natriuretic peptide. Produced from bacteria
|
|
Nesiritide: what does it do?
|
Reduces filling pressures and dyspnea in acute decompensated CHF (Class IV)
|
|
Nesiritide: route
|
IV
|
|
Nesiritide: AE
|
Reduces renal function --> increased creatinine.
|
|
Why is BNP called "brain" natriuretic peptide?
|
Because it was discovered there first.
|
|
What are three components that are part of "neurohumoral stimulation"?
|
- The sympathetic nervous system
- The renin-angiotensin system - The aldosterone system |
|
Hydralazine: what is it?
|
Vasodilator
|
|
Hydralazine: M of A
|
Unknown
|
|
Hydralazine: best paired with what?
|
With a beta-blocker (due to reflex tachycardia)
|
|
An effect similar to that caused by beta-blockers can be achieved with what durg combination?
|
Hydralazine (direct vasodilator)+ nitrates
(But ACEi and ARBs are better) |
|
Hydralazine: AE
|
A "wicked" reflex tachycardia
|
|
LVH: women vs. men
|
Women have more of a propensity to remodel pathologically
|
|
How do we treat diastolic heart failure?
|
Almost the same way as systolic heart failure:
1. Reduce the congestive state 2. Maintain atrial contraction 3. Treat and prevent ischemia 4. Control HTN |
|
What are the drugs that increase longevity?
|
1. ACEi
2. Beta-blockers 3. Aldosterone antagonists |